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Introduction: The management of segmental long-bone defects is a challenge. The literature has 
described many techniques, but each is fraught with specific difficulties. Masquelet’s technique of 
induced membrane is now a reference surgical procedure for the treatment of complex lesions requiring 
bone regeneration. The concept of induced membrane was introduced by Alain-Charles Masquelet in 
1986. The Masquelet method consists in formation of an induced membrane by a foreign body which 
has secretory properties, influencing positive on the regeneration and strengthening of the cancellous 
bone grafts. Aim: to investigate the morphological properties and characteristics of induced membrane 
which was modeled in an experimental group of rabbits in order to asses and to optimize the effectiveness 
of the Masquelet method in the clinic.
Materials and methods: Experimental work was done using a group of rabbits (n=10) with the 
weight 5,5±0,5kg and the age 5 months. The investigation had 3 steps. The first step of the study 
consisted in creating the bone defect, filling it up with an antibiotic-impregnated cement spacer and 
stabilizing it with a plate. The second step of the study was 21 days later, consisting in incision of the 
induced membrane, removing the spacer and filling up the space with cancellous bone chips collected 
from iliac crest. At this stage we sacrificed 5 rabbits in order to perform the histological and 
morphological examination. At the sixth week we switched to the third step – ablation of metal 
construction and the radiological control exam. At this stage we sacrificed 5 rabbits to study the 
morphological aspect of the healed bone.
Results: The histo-morphological examination performed at the 21 days demonstrated the 
presence of an inflamator process characterized by neutrophilic, eosinophilic elements and 
regeneration’s elements – fibroblasts. Also, it was determined a pseudo synovial metaplasia and a villous 
hyperplasia with formation of an synovial epithelium on the internal face of the induced membrane. The 
histo-morphological exam performed at the 6 weeks has demonstrated the continuation of the 
neoformating process and of the bone modelation, the regeneration process prevailed over the 
inflammatory one. The morphological aspect was formed by agglomerations of fibroblasts, myoblasts 
and collagen and numerous vascular buds, that promote a good neoangiogenesis and osteogenesis of the 
bone.
Conclusion: The morphological study demonstrated an intense process of cell proliferation and 
differentiation, which highlights the biological role of induced membrane by foreign body with secretion 
of the osteoinductive factors, promoting the vascularization and corticalization of the bone. The 
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Masquelet method is an effective method that allows getting the consolidation of the bone in case of 
critical size bone loss. 
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Introduction: Treatment adherence is an important element in the management of every chronic 
disease. For the patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors 
(TKI) the remarkable benefits brought by the medication may be significantly undermined by the patient 
low adherence to treatment. 
Materials and methods: We conducted a qualitative and observational study, which was 
performed between October 2015 and December 2015, on patients diagnosed with CML under treatment 
with TKI at I-st Medical Clinic-Hematology, Clinical Emergency County Hospital Targu Mures, 
Romania. The sampling of patients was simple-random, consisting of 32 patients with CML-chronic 
phase, >18 years old, with >12 months of treatment with TKI, median age was 55 years, 67.47% of the 
patients were males and 62.5% of the patients were treated with imatinib 400 mg/QD. Physician-reported 
adherence (observed adherence) was evaluated, for the last 3 months, using the Proportion of Days 
Covered (PDC) method and patient-reported adherence (experienced adherence) using a self-reporting 
questionnaire with 10 items regarding adherence to treatment; demographic data were collected too. The 
following statistical analysis was used: descriptive statistic, Fisher Exact test, unpaired t-test.
Results: PDC was <0.9 (low adherence) in 3 patients and 0.9-1 in 5 patients (medium adherence); 
Total lower adherence (low + medium) was 25%, patients being younger (p=0,044), but adherence was 
not correlated with gender, TKI treatment length, urban/rural place of living (p>0.05). 46.88% of the 
patients admit omission of doses, 73.33% of them attributing it to forgetfulness (33.33% rarely forgot, 
40% sometimes), the other 26.66% to medication adverse effects or to a sense of feeling sick.
Conclusion: PDC estimation of adherence was more optimistic compared to experienced 
adherence. Due to the unavoidable errors Associated with patient self-report, the rate of non-adherence 
is probably underestimated. Because the adherence to chronic medication in general and to TKI in 
particular is multifactorial, further quantitative, multiparameter and multicenter studies are necessary.
Keywords: chronic myeloid leukemia, treatment adherence, tyrosine kinase inhibitors.
173
